ABSTRACT Background: There is some evidence that increased maternal intake of omega-3 (n-3) long-chain polyunsaturated fatty acids (LC-PUFAs) during pregnancy may reduce the incidence of immunoglobulin E (IgE)-mediated allergic disease. Objective: We aimed to evaluate prenatal n-3 LC-PUFA dietary exposure in observational studies and n-3 LC-PUFA supplementation in randomized controlled trials (RCTs) on outcomes of IgEmediated allergic disease. Design: We conducted searches of the Cochrane Central Register of Controlled Trials, PubMed, Ovid MEDLINE, EMBASE, CINAHL, SCOPUS, and Web of Science to 30 July 2015. We included prospective cohort studies that showed an association between maternal fish or n-3 LC-PUFA intake during pregnancy and RCTs with a prenatal intervention to modify maternal n-3 LC-PUFA intake and outcomes of allergic disease (eczema, rhino-conjunctivitis, asthma) or sensitization in the offspring. Results: A total of 13 publications from 10 prospective cohort studies and 7 publications representing 5 unique RCTs were included. Three RCTs were combined in a meta-analysis for selected outcomes. Nine of 13 observational study publications and 5 of 7 publications from RCTs found a protective association between increased prenatal n-3 LC-PUFA or fish intake and incidence of allergic disease symptoms in the child. Meta-analysis was limited because of the heterogeneity of the RCTs. Pooled results showed a significant reduction in the incidence of "atopic eczema," "any positive SPT [skin-prick test]," "sensitization to egg," and "sensitization to any food" in the first 12 mo of life [RRs (95% CIs): 0.53 (0.35, 0.81), P = 0.004; 0.68 (0.52-0.89), P = 0.006; 0.55 (0.39-0.76), P = 0.0004; and 0.59 (0.46, 0.76), P , 0.0001, respectively]. Conclusions: Our systematic review and meta-analysis was suggestive of benefits of increased n-3 LC-PUFAs in the maternal diet and outcomes of childhood allergic disease. However, due to the inconsistency in results, the hypothesis linking maternal n-3 LC-PUFA intake to childhood allergic disease cannot unequivocally be confirmed or rejected.
INTRODUCTION
There is general consensus that the worldwide prevalence of allergic disease has escalated too rapidly to be attributed to genetic changes alone. Although the cause may have mixed etiology, it is widely accepted that the current allergy epidemic is attributable to a changing environment, including lifestyle factors and diet. Dietary ratios of n-6 to n-3 PUFAs have changed from an equal balance of n-6:n-3 (1:1) to almost 30:1 (n-6:n-3) in some Western cultures (1) . These profound changes in the type of fat consumed parallel the increasing prevalence of atopy and allergic disease (atopic eczema, IgE-mediated rhino-conjunctivitis, IgE-mediated allergic asthma), posing the hypothesis that this imbalance may have a causal relation. When consumed, n-3 and n-6 PUFAs compete for the same enzymes required for conversion into their long-chain (LC) 7 derivatives (LC-PUFAs). Diets high in n-6 PUFAs due to the increased consumption of linoleic acid (18:2n26)-rich vegetable oils and arachidonic acid (20:4n26) from meat result in a predominance of proinflammatory arachidonic acid in tissues. This leads to biochemical and physiologic changes consistent with a greater propensity to an inflammatory allergic response (2) . Plausible mechanisms therefore exist whereby diets high in n-3 LC-PUFAs may modulate the development of IgE-mediated allergic disease and regulate immune responses. Data from clinical and animal studies suggest that dietary n-3 LC-PUFAs in early life may influence immune system development and immune cell function, reducing inflammatory responses (3); however, clinically beneficial effects are more conflicting.
Initiating events of allergic disease occur early in immune development, with antigen-specific reactivity detected in cord blood at birth and as early as 23 wk of gestation in the fetus (4) . Hence, it is our hypothesis that there may be a window of opportunity to modulate the fetal immune system before it has been programmed to an allergic phenotype by increased maternal supply of anti-inflammatory n-3 LC-PUFAs (5) .
Published reviews on the effect of n-3 LC-PUFAs in the primary prevention of allergic disease have been conducted; however, not all are systematic and most do not include observational studies (5) (6) (7) (8) (9) .Two reviews pooled results of n-3 LC-PUFA exposure during fetal life, infancy, and childhood, increasing the variability of results and potentially diluting any causal effect (5, 7) . In the complex field of nutrition and health outcomes, multiple levels of research evidence should be considered when establishing causal effects (10) . We therefore included epidemiologic studies observing n-3 PUFA/LC-PUFA dietary exposures and randomized controlled trials (RCTs) with an n-3 LC-PUFA intervention and subsequent associations or effects on IgE-mediated allergic disease. By limiting this systematic review to exposures or interventions that commenced in the intrapartum period, we aim to develop a clearer understanding of the effect to the developing fetus, before commencement of the progression of atopy ("atopic march") and establishment of allergic disease symptoms.
METHODS
Our systematic review is reported according to the PRISMA (Preferred Reporting Items for Systematic Reviews and MetaAnalyses) guidelines (11) . We included all prospective studies, including longitudinal observational studies and RCTs. Observational studies were included if they examined an association between maternal fish or n-3 LC-PUFA intake during pregnancy and clinical outcomes of allergic disease or sensitization in the offspring. RCTs and quasi-randomized trials that evaluated an intervention modifying maternal n-3 LC-PUFA intake during pregnancy with a parallel control group or placebo on the clinical outcomes of allergic disease (eczema, rhino-conjunctivitis, asthma) or sensitization in the offspring were eligible for inclusion in the review. Animal studies, cross-sectional studies, and retrospective and case-control studies were excluded. All of the included participants were pregnant women, regardless of gestation, and their offspring. There was no restriction placed on the atopic predisposition of the women, their offspring, or the age of followup. Included studies were required to report maternal intake of n-3 LC-PUFAs via dietary intake or supplements during the pregnancy period. Studies of maternal n-3 LC-PUFA consumption or supplementation in the postnatal period only (breastfeeding or direct supplementation of the infant) were excluded.
The primary outcome measure of this review was the incidence of atopic disease (i.e., IgE-mediated allergic disease) or sensitization in the offspring during infancy, childhood, or adolescence. The presence of IgE-mediated allergic disease is defined as a clinician diagnosis, parent report of symptoms of allergic disease, or parent report of a physician's diagnosis. Sensitization is defined as a positive skin-prick test (SPT) or IgE serology indicating sensitization. Studies that reported immune biomarkers by laboratory assessment in the absence of evaluation of symptoms or clinical diagnosis of allergic disease in the offspring were excluded.
A comprehensive search for publications was undertaken using the following databases from inception to 30 We supplemented our search by cross-checking the reference lists of relevant retrieved publications identified by the search and recent review articles. No date restrictions were imposed, although results were limited to human studies. The titles and abstracts of all articles retrieved by the search were reviewed by one author (KPB) to assess eligibility for inclusion in the review. If there was insufficient information in the abstract to warrant exclusion of an article, the full text of the article was retrieved to determine eligibility. Any uncertainty with regard to the inclusion of publications was resolved after discussion with a second reviewer (MM).
Data relating to dietary exposure or interventions, outcomes, potential effect confounders, and study quality were extracted by use of a standardized data extraction form. Extracted information included characteristics of study participants, type of exposure measure (cohort), maternal exposure to/supplementation of fish or n-3 LC-PUFAs, timing and length of intervention, and type and timing of outcome measures. Studies included in this review varied markedly in terms of the methods, timing, and type of intervention and timing and type of reported outcome measures. We therefore reported study results for all observational studies and a number of RCTs descriptively, including their applicability and limitations. Meta-analysis was considered only for RCTs with comparable timing of outcome assessment (age of offspring). Outcomes of allergic disease that met this criterion include the following: "atopic eczema," "sensitization to egg," "sensitization to any food," and "any sensitization." Other outcomes, including asthma symptoms and rhino-conjunctivitis, were unable to be combined due to heterogeneity with definition of outcomes between studies and the young age of follow-up (2 and 3 y). Preplanned analysis of allergic disease outcomes were grouped according to the age of the offspring at the time of outcome assessment. Sensitivity analysis was conducted to investigate the influence of a single study on the overall estimate; P , 0.05 was considered to be significant for all tests. All analyses were performed by using Review Manager Software 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration), and heterogeneity was assessed by comparing the CIs of the results of individual studies and with the I 2 statistic. When there was an absence of significant heterogeneity, the results were pooled by using a fixed-effects model. When substantial heterogeneity was detected (I 2 . 50%), possible causes were explored, and a random-effects model was used. Continuous outcomes are reported as mean differences with 95% CIs.
RESULTS
The search returned a total of 1133 publications. After removal of duplicates, 543 publications remained. Of these, 478 publications were excluded because they did not meet the predefined inclusion criteria. A total of 65 full-text articles were reviewed for eligibility, resulting in 45 exclusions for reasons listed in Figure  1 . Thirteen publications from 10 unique prospective cohort studies and 7 publications representing 5 unique RCTs were included in the review. Three trials with comparable timing of outcome assessments for "any sensitization," "sensitization to egg," and "sensitization to any food" and 2 trials with atopic eczema outcomes at 12 mo were combined in the meta-analysis.
Participants
All of the studies were conducted in industrialized countries. Seven of the observational studies enrolled healthy pregnant women presenting at antenatal or obstetric care clinics between 5 and 39 wk of gestation, irrespective of atopy status (12) (13) (14) (15) (16) (17) (18) . One study from The Netherlands selectively enrolled participants depending on their nationality (19) and another restricted enrollment to Danish-speaking participants (20) . Two remaining studies enrolled full-term infants, collecting maternal diet information retrospectively (21) (22) (23) (24) . One of these studies (with 3 publications included in this review) was a nested nutrition follow-up of the Diabetes Prediction and Prevention (DIPP) study in Finland (22) (23) (24) . Mothers were enrolled after birth and confirmation that their child was at risk of developing diabetes by the presence of human leukocyte antigen in cord blood. Characteristics and results of observational studies are presented in Table 1 .
All of the included RCTs recruited women during the antenatal period from clinical care settings. Four of the 5 RCTs enrolled women who were at risk of delivering a fetus with atopic disease (i.e., first-degree relative with history of allergic disease) (25) (26) (27) (28) (29) ; however, only one of these trials confirmed atopy in the mother by SPT before enrollment (30) . The remaining trial included women attending their routine 30-wk midwife clinic visit, regardless of atopy status (31) . Characteristics and results of RCTs are presented in Table 2 . no difference between groups for "any asthma," IgE-associated asthma, "any eczema," "any rhinoconjunctivitis," IgE-associated rhino-conjunctivitis at 24 mo, or cumulative incidence at 0-24 mo
PRENATAL OMEGA-3 LC-PUFAS AND ALLERGY 
Exposure/intervention
Observation of maternal dietary n-3 PUFA intake during pregnancy in cohort studies was ascertained by the use of diet history questionnaires (DHQs) or food-frequency questionnaires (FFQs). FFQs were either self-or interviewer-administered by phone or face-to-face. The timing of administration of the questionnaire varied between the first (19), second (17) , and third (13, 15, 17, 20, (22) (23) (24) trimesters or ad hoc time points throughout pregnancy relative to study enrollment (16, 18) . All of the studies required the women to complete the FFQ retrospectively from 3 d (21) to 3 mo (12, 14, 19 ) postpartum. The intensity of questioning in FFQs varied from 35 to 360 items, and total dietary fish exposure varied between 83 g/wk and 46 g/d (Table 1) .
The intervention in 4 of 5 RCTs consisted of fish-oil capsules. Capsules varied in composition and dose of n-3 LC-PUFAs, ranging from 900 to 3700 mg of total n-3 LC-PUFAs/d (26, (29) (30) (31) . One RCT supplied women with 2 3 150-mg portions of farmed salmon to consume twice per week, equivalent to 3450 mg n-3 LC-PUFAs/wk (the control group continued their habitual low-fish diet) (27) . Placebos used in the doubleblind RCTs consisted of olive oil (30, 31) , soy oil (25, 26) , or vegetable oil (28, 29) that did not contain n-3 LC-PUFAs. One study had 2 control groups (olive oil and "no oil") (31) . The timing of the intervention commenced between 20 and 30 wk of gestation and ceased at delivery of the infant in 4 of the included unique RCTs (27, (29) (30) (31) . One RCT continued supplementation of mothers for 3.5 mo into the postpartum period (25, 26) .
Clinical outcomes
The clinical indication of allergic disease in the offspring in observational studies and RCTs was diverse. Study outcomes reported included the following: symptoms of wheeze, eczema, and rhinitis by parent report with the use of the International Study of Asthma and Allergy in Childhood (ISAAC) questionnaire (validated for use in 6-to 7-y-old children) (13, 15, 16, 18, 19, 22, 23) ; nonvalidated health questionnaire (21); parent report of physician diagnosis of asthma or eczema (12, 14, 20) ; asthma medication data from a social insurance database (22) or patient registry (31); and clinical examination by nurse or physician (17, (25) (26) (27) (28) (29) (30) . Five of the included observational studies and 4 of the RCTs assessed atopy outcomes with the use of either total and specific serum IgE analysis (24, 32) , SPT (13, 14, 25, 26, (28) (29) (30) , or a combination of both outcomes (12, 27) . Individual or multiple outcomes were reported as cumulative incidences or point prevalences (Tables 1 and 2 ). The ages of the offspring at assessment of study outcomes varied between 6 mo and 8 y in observational studies (Table 1 ) and between 6 mo and 3 y in RCTs (Table 2) , with the exception of one registry linkage trial that reported history of asthma diagnosis at 16 y (31).
Quality of observational studies
All of the included observational studies were assessed for methodologic quality by using the Newcastle-Ottawa Scale (33) . It includes a "star system" (*) in which a study is judged on 3 domains: representativeness of study group selection (4 items), comparability of groups (2 items), and ascertainment of either the exposure or outcome (3 items) (see Table 3 ). Some level of bias was evident in all of the cohort studies, predominantly with regard to the ascertainment of maternal exposure to n-3 LCPUFAs and/or assessment of allergic diseases outcomes. FFQs and DHQs are applicable to large cohorts and provide information on a wide range of foods. However, there are many limitations of these instruments, including dietary misreporting, which leads to dietary misclassification of intake and/or portion sizes. The detection of modest nutrient associations when using Each study is judged on three domains receiving a "*" to signify quality of each item within representativeness of study group selection (4 items); comparability of groups (2 items); and ascertainment of either the exposure or outcome (3 items).
an FFQ for dietary assessment is unlikely (34, 35) . This is especially true for reliable estimates of absolute amounts of dietary fats (36, 37) . A number of studies did not capture fish type (e.g., "fatty fish") (Table 1) , which may be problematic because there is significant variation in the amount of n-3 LC-PUFA intake depending on the type of fish consumed. Dietary intake over the preceding period of 4 wk to 3 mo was documented retrospectively and may be subject to recall bias. With the exception of 2 studies (17, 20) , maternal diet was assessed only once (between 12 and 40 wk of gestation), which may not be indicative of diet throughout the whole of pregnancy, as shown by one of the Japanese studies (18) . These authors conducted dietary assessment at "any time" between the 5th and 39th week of pregnancy and reported that 30% of respondents had substantial changes in their diet in the previous month.
Substantial geographic variation existed between cohort studies in relation to total fish intake, fish subgroups, and the number of types of fish consumed (38) . Decreased variability between categories of fish or n-3 PUFA intake was evident in 4 included studies from the Netherlands (15, 19, 23, 24) , a country where there is generally low fish consumption. In one study, of the 2760 included women, just 7% consumed fish .1.5 times/wk (30 g/d) and only one woman ate fish daily (15) . In contrast, the mean fish intake in 2 Japanese studies was 48 g/d, with low variability between fish-intake quartiles due to the generalized high fish consumption. The presence of allergic disease symptoms in the offspring were self-reported in the majority of studies that used the ISAAC questionnaire (or a "modified" version). The ISAAC is a standardized questionnaire and has been validated in children aged 6-7 and 13-14 y old; however, most children in the included cohort studies were younger (15) (16) (17) (18) (19) (21) (22) (23) (24) . The ability to differentiate IgE-mediated allergic disease was diminished because only 4 of the 13 publications assessed atopy in the child (SPT or serum IgE) (12) (13) (14) 24) . Attrition bias was possible in a number of studies with follow-up rates ,80% (13, 15, 16, (18) (19) (20) (22) (23) (24) . When comparing population characteristics of participants and nonparticipants, participants tended to display healthier lifestyle habits, higher maternal and paternal educational levels, and higher income levels (18, 20) . One study with 3 publications included only infants at risk of developing diabetes by the presence of human leukocyte antigen in cord blood (DIPP study). Children with type 1 diabetes have been reported to have a reduced incidence of asthma and allergic diseases compared with the general population; therefore, this genetic susceptibility may further decrease the generalizability of this study's findings.
Quality of RCTs
Two review authors (KPB and MM) assessed the risk of bias for each trial using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (39) . A summary of the risk of bias associated with each RCT is shown in Table 4 . Two trials lacked sufficient clarity when reporting concealment of the allocation sequence (25) (26) (27) and were therefore assessed as having an unclear risk of bias. Blinding of participants was endeavored by image-matching capsules in 4 double-blind RCTs (25, 26, (28) (29) (30) (31) . One of these trials included a "no supplement" group, which may have resulted in unblinding of participants and personnel (31) . All of the trials that used fish-oil capsules reported side effects of "fishy burps," potentially risking unblinding of participants; however, objective outcome assessment, such as SPT, reduced the risk of performance bias. One single-blind trial that supplied salmon portions to women in the intervention group and no salmon in the control group was assessed as having a high risk of bias because the participants could not be blinded (27) . This trial also had a high attrition rate, with only 62% of the control group attending the 6-mo followup, which is well below the minimum follow-up considered acceptable for minimizing attrition bias ($80%) (27) . The risk of bias from incomplete outcome data reporting was high in 2 other trials (26, 30) . One trial had significantly higher attrition in the treatment group (15%) than in the control group (2%) due to side effects perceived to be associated with the study product (30) . Another excluded 25 mothers (17%) from the analysis because they did not complete supplementation for the requested period (26) . Such postrandomization exclusions and attrition can contribute to systematic loss to follow-up and increase the risk of bias in already small and underpowered samples. Other bias was unclear in one registry linkage study due to a lack of clarity with regard to reporting of standardization of outcome assessments (31). Data were ascertained by searching the Danish National Patient Registry, a mandatory national hospital discharge register for asthma and allergic disease-related coding. Although the long-term follow-up rate for this study is outstanding, the overall rate of diagnosed asthma is much lower than reported in other studies. It is unknown how the diagnosis of asthma was made and likely that there was an underrepresentation of milder cases treated outside of the Danish hospital system. Of the 5 included RCTs, 4 studies used SPT as an outcome measure to determine atopy status of the offspring (26, 27, 29, 30) ; however, definitions of sensitization were inconsistent. Two studies used the standard clinical definition of wheal size $3 mm as the diagnosis of sensitization (27, 29) . Another 2 studies that conducted 6-and 12-mo follow-ups of infants included results of $2-mm wheal size in the analysis of sensitization (26, 30) . The rationale for this criterion as opposed to the standard clinical definition was not reported. There is evidence that SPT reactions in the very young (,12 mo) are often diminished, which makes interpretation difficult (40) .
Results of observational studies Table 1 summarizes all of the identified studies that investigated the association between maternal n-3 LC-PUFA or fish intake and allergic disease outcomes in the offspring. Eight of the 13 included studies found a protective association between increased n-3 LC-PUFA or fish intake in the prenatal diet and incidence of one or more allergic disease symptoms in the child (12-14, 17, 18, 20-22) . One of these studies assessed maternal diet by phone interview in addition to self-completed FFQ; however, a significant association of increased fish intake on asthma outcomes was only evident from phone interview data (20) . Four studies showed no association between maternal n-3 LC-PUFA or fish intake and allergic disease outcomes (15, 16, 23, 24) . One study reported an adverse association in one category of fish intake (19) .
Eczema
The incidence of eczema was reported in 8 studies, with 4 of these showing that higher fish/n-3 LC-PUFA exposure was associated with a reduction in the risk of eczema in the offspring of between 27% and 43%. Fish intake of .205 g/wk (17) and fish intake 2.5 times/wk compared with no intake (12) were protective against the risk of eczema at 12 mo. High compared with low fish intake was inversely associated with parent reported, doctor diagnosed eczema at 24 mo in one study (21) and fish intake of $1 time/wk compared with never was associated with a decreased risk of doctor-confirmed eczema and currently treated eczema (13) . Two separate studies from Japan found no association between increased maternal fish intake and eczema (16, 18) , and one of the publications from the DIPP study found no association between increased total n-3 PUFAs, DHA, or EPA with eczema (16, 18, 23) . One study from the Netherlands reported that the midcategory of intake (35-69 g/wk) was associated with the highest eczema rate, whereas the lower and higher categories of fish intake (1-34 and .70 g/wk) showed no association with overall risk of eczema (19) .
Rhino-conjunctivitis
Three studies assessed symptoms of rhino-conjunctivitis (13, 20, 23) . One study concluded that maternal fish intake once or more per week compared with never was protective for "doctor-confirmed hay fever" at 5 y (13). Two studies found no significant association between no maternal fish intake compared with high-frequency intake and rhino-conjunctivitis (20) or between increased total n-3 PUFAs, DHA, or EPA and rhino-conjunctivitis (23).
Asthma/wheeze
Nine studies assessed the incidence of asthma or symptoms of wheeze. Low maternal fish consumption was inversely related to parent report of physician diagnosis of asthma and wheezing symptoms at 18 mo and 7 y (20), atopic wheeze (12) , and persistent wheeze at 6.5 y (14) . Two studies reported a protective association of an increased total maternal n-3 LC-PUFA (but not fish) intake on wheeze at 24 mo (18) and asthma at 5 y (22) . One Japanese study showed that high maternal n-3 PUFA intake (via a-linoleic acid, 18:3n23) was associated with a reduced risk of wheeze (16) . The 3 remaining studies (2 from the Netherlands) found no significant association between increased fish or n-3 LC-PUFA consumption and wheeze (23) , risk of asthma (22), or asthma symptoms (13) .
Sensitization
Three studies reported the association of fish or n-3 PUFA intake on total and specific IgE at 2 y (21), 4 y (12), and 5 y (24), all showing no significant association. One of these studies conducted further follow-up at 6.5 y of age with SPT and reported that fish intake of $2.5 times/wk was protective against sensitization to house dust mite (12) . One study that performed an SPT at 5 y of age found no significant association between maternal fish intake and atopic sensitization (13) . Table 2 summarizes all of the identified RCTs that investigated the effect of prenatal n-3 LC-PUFA supplementation (or supplied fish portions) on allergic disease outcomes in the offspring. Of the 7 publications (from 5 unique RCTs), 5 found a protective effect on $1 clinical outcomes of allergic disease or sensitization at $1 assessment time points.
Results of RCTs

Eczema
The incidence of IgE-mediated eczema between children born to mothers supplemented with n-3 LC-PUFAs during pregnancy and control groups was assessed between 0 and 3 y in 4 RCTs and reported in 6 of the included publications (25) (26) (27) (28) (29) (30) . One trial that conducted follow-up of children over a 2-y period found a significant reduction in the cumulative incidence of atopic eczema at 12 and 24 mo (25, 26) . Another study reported a nonsignificant protective effect of the intervention at 12 mo, with no effect when reassessed at 3 y (28, 29) .
The 2 remaining studies found no effect of n-3 LC-PUFA supplementation on eczema (27, 30) , although one did report a significant reduction in severity of disease (30) . Results from RCTs that reported outcomes of "atopic eczema" (eczema symptoms and positive SPT) at 12 mo of age were combined in a meta-analysis showing a significant reduction in the incidence of atopic eczema (RR: 0.53; 95% CI: 0.35, 0.81; P = 0.004) (Figure 2) . Both of these trials also reported outcomes of incidence of "any" eczema (eczema symptoms with or without positive SPT) at 12 mo, showing no significant effect of the intervention (RR: 0.85; 95% CI: 0.67, 1.07; P = 0.16) (Figure 3 ).
Rhino-conjunctivitis
There was no difference between the groups in the cumulative incidence of "any rhino-conjunctivitis" or "IgE-mediated rhinoconjunctivitis" in the 2 studies that reported this outcome at 0-24 mo (25) and 0-3 y (29) (RR: 0.81; 95% CI: 0.44, 1.47; P = 0.49) (Figure 4) .
Asthma
Asthma and/or symptoms of asthma were assessed in 5 of the 7 included publications at different ages and with a variety of outcome measures, which prevented meaningful meta-analysis. There were no differences in asthma or wheeze with or without sensitization at 6 mo (27), 12 mo (30), 24 mo, 0-24 mo (25), or 3 y (28).
FIGURE 4
Forest plot of randomized controlled trials comparing maternal n-3 LC-PUFA supplementation during pregnancy with placebo on cumulative incidence of IgE-mediated rhino-conjunctivitis (rhino-conjunctivitis with a positive skin prick test) in the offspring within the first 3 y of life. In this fixedeffects model, squares represent RRs and error bars represent 95% CIs. The diamond represents the overall effect estimate. There was no heterogeneity between studies. LC-PUFA, long-chain PUFA; M-H, Mantel-Haenszel.
FIGURE 5
Forest plot of randomized controlled trials comparing maternal n-3 LC-PUFA supplementation during pregnancy with placebo on the incidence of a positive skin prick test result to any allergen extracts tested in the offspring within the first 12 mo of life. In this fixed-effects model, squares represent RRs and error bars represent 95% CIs. The diamond represents the overall effect estimate. There was no heterogeneity between studies. LC-PUFA, long-chain PUFA; M-H, Mantel-Haenszel.
One registry-based follow-up RCT included asthma diagnosis as an outcome and reported a significant reduction in "any asthma" and "allergic asthma" at 16 y of age in the fish-oil-supplemented group compared with the "olive oil" control group. However, a significant positive effect on "any asthma" and "allergic asthma" was also evident in the second "no oil" control group (31) .
Sensitization
Sensitization to common allergens was assessed by SPT at 6 mo (27), 12 mo (26, 27, 29, 30), 24 mo (25), and 3 y (28). Three RCTs with sensitization outcomes at 12 mo of age were combined in meta-analysis and showed a significant protective effect of the intervention on the period prevalence of "any positive SPT" (RR: 0.68; 95% CI: 0.52, 0.89; P = 0.006) ( Figure 5 ). The trial with the salmon portion-based intervention also measured total IgE at birth and 6 mo of age, with no difference between the groups (27) . A meta-analysis of sensitization to individual allergen extracts showed a significant reduction in "sensitization to egg" at 0-12 mo (RR: 0.55; 95% CI: 0.39, 0.76; P = 0.0004) ( Figure 6 ) and "sensitization to any food" at 12 mo (RR: 0.59; 95% CI: 0.46, 0.76; P , 0.0001) (Figure 7 ).
DISCUSSION
Our systematic review and meta-analysis shows that increased prenatal intakes of n-3 LC-PUFAs in observational studies and RCTs are suggestive of benefits. However, due to the inconsistency of results, the hypothesis linking increased maternal n-3 LC-PUFA intake to a protective association or effect on childhood allergic disease cannot unequivocally be confirmed or rejected. Despite the challenges of capturing and comparing outcomes of a dynamic disease, some of the consistency observed across the study designs used is noteworthy (41) . It is widely acknowledged that causal inferences based on results from studies of nutritional epidemiology that have been confirmed by results from RCTs represent more persuasive evidence than those elucidated from observational data alone (10) . Observational studies showed a trend toward a protective association of increased maternal n-3 LC-PUFAs on the incidence of eczema and wheeze or asthma. Similar results were evident in RCTs for eczema but not for wheeze or asthma, perhaps due to the age of the child when outcome assessments were conducted (1-3 y). The most significant and consistent outcome in RCTs was a reduction in the incidence of sensitization (positive SPT) in the n-3 LC-PUFA group. Although the presence of an IgEmediated reaction to a food or inhalant allergen generally confirms that an individual is "atopic," the relation between sensitization and symptoms of allergic disease is known to be complex and dynamic. This finding may have some correlation to the reduction in respiratory disease evident in observational studies in school-aged children. It is well documented that early sensitization to food allergens (especially egg) is shown to be a valuable predictor of subsequent sensitization to aero-allergens and allergic respiratory diseases (42) (43) (44) (45) .
Heterogeneity between study designs may, in part, be explained by the limited number of well-powered high-quality RCTs with long-term follow-up and consistent age-appropriate outcomes. Whereas epidemiologic studies have the potential to assess longterm health effects of nutrient intake, the possibility for residual confounding cannot be discounted, particularly when assessing single-nutrient exposure (35) . The protective associations seen in the offspring of women with increased intakes of n-3 LC-PUFAs FIGURE 6 Forest plot of randomized controlled trials comparing maternal n-3 LC-PUFA supplementation during pregnancy with placebo on the incidence of a positive skin prick test to hen's egg in the offspring in the first 12 mo of life. In this fixed-effects model, squares represent RRs and error bars represent 95% CIs. The diamond represents the overall effect estimate. There was no heterogeneity between studies. LC-PUFA, long-chain PUFA; M-H, Mantel-Haenszel.
FIGURE 7
Forest plot of randomized controlled trials comparing maternal n-3 LC-PUFA supplementation during pregnancy with placebo on the incidence of a positive skin prick test to any food extract in the offspring in the first 12 mo of life. In this fixed-effects model, squares represent RRs and error bars represent 95% CIs. The diamond represents the overall effect estimate. There was no heterogeneity between studies. LC-PUFA, long-chain PUFA; M-H, Mantel-Haenszel. during pregnancy may not be due to this exposure, but rather serve as a proxy indicator for a number of other maternal characteristics that are associated with the healthy development of their offspring (46) . These confounding factors are difficult to fully accommodate in data analysis, even when acknowledged. In addition, dietary intake in epidemiologic studies is notoriously difficult to measure and often results in variations in findings (47) . Flaws in standard tools for dietary assessment (FFQ or DHQ) are well documented and cannot be ignored (35, 37, 47, 48) . This issue was emphasized in the large Danish birth cohort (n = 28,936) that observed an association between fish intake and asthma diagnosis (20) . Self-completed FFQ data showed a null association between fish intake and asthma diagnosis at 18 mo and 7 y; however, analysis of fish-intake data collected by telephone interview showed a significant inverse relation (20) .
The main strength of our integrated systematic review, which included both prospective observational studies and RCTs, lies in the detailed search strategy, rigorous and transparent methods, and the qualitative and quantitative synthesis of differing methodologies. However, the risk of publication bias cannot be excluded because only published studies were included in metaanalysis. Using well-established processes for conducting systematic reviews (49) we determined that observational studies and many RCTs had methodologic weaknesses, making it difficult to draw any strong inferences from this review. There have been numerous studies that investigated maternal dietary n-3 LC-PUFA status on the regulation of the fetal immune response (50) (51) (52) (53) (54) . These studies reported plausible biological mechanisms that may modulate the development of allergic disease in infants with a genetic risk. However, as is evident in this and other reviews of increased maternal supply of n-3 LC-PUFAs and outcomes of allergy (5-9, 55-57), results are promising but inconsistent. Continued supplementation of breastfeeding mothers during the early postpartum period to compensate for the natural decline in maternal plasma n23 LC-PUFAs may provide additional benefit to the development and maturation of the infant immune system and is worthy of further investigation (58) . Further evidence from well-powered, high-quality trials of comparable methodology and standardized, objective outcome assessments are essential to investigate the optimal dose and tolerability and to conclusively establish benefits. Due to the dynamic nature of allergic disease, RCTs should continue followup of children throughout childhood, at least until school age to investigate if the significant protective effects of maternal n-3 LC-PUFA supplementation seen on eczema and sensitization in early life will affect the progression of the atopic march.
It is generally agreed that the increasing number of people affected by allergic disease is a consequence of our 21st-century lifestyle. Almost certainly this increase is attributable to genetic and environmental factors, including, but not limited to, diet. Diet is easily modifiable; perhaps this simple, low-cost approach of increasing n-3 LC-PUFA intake during pregnancy may offer the best opportunity for a primary prevention strategy, decreasing the burden of allergic disease for future generations.
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